Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryvu TherapeuticsLTS:0RKT 65 Debt-to-Equity is 1.78 as of Mar. 2026, which is 5833% above its 10-year median of 0.03. GuruFocus rates LTS:0RKT with a GF Score™ of 65/100 and a GF Value™ of zł77.23. The stock has 3 warning signs investors should review. Among 954 Biotechnology companies, Ryvu Therapeutics ranks worse than 93.4% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Ryvu Therapeutics's Debt-to-Equity or its related term are showing as below:
LTS:0RKT'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 1.78
Current: 1.78
During the past 13 years, the highest Debt-to-Equity Ratio of Ryvu Therapeutics was 1.78. The lowest was 0.00. And the median was 0.03.
LTS:0RKT's Debt-to-Equity is ranked worse than 93.4% of 954
companies
in the Biotechnology industry
Industry Median: 0.16
vs LTS:0RKT: 1.78
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Ryvu Therapeutics Debt-to-Equity Related Terms
Ryvu Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RKT vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Ryvu Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryvu Therapeutics (LTS:0RKT) has a Debt-to-Equity of 1.78 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ryvu Therapeutics and its competitors. This is 5833% above median its historical median of 0.03. According to the industry distribution chart, Ryvu Therapeutics ranks #891 out of 954 companies in the Biotechnology industry, placing it in the top 93.4%.
Is Ryvu Therapeutics' Debt-to-Equity too high?
Ryvu Therapeutics' current Debt-to-Equity of 1.78 is 5833% above median its 10-year median of 0.03. The Biotechnology industry median Debt-to-Equity is 0.16. Ryvu Therapeutics' value of 1.78 is 1012.5% above this industry median. Based on the distribution chart, Ryvu Therapeutics ranks #891 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ryvu Therapeutics has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #891 out of 954 companies for Debt-to-Equity. This places Ryvu Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Ryvu Therapeutics' value of 1.78 is 1012.5% above this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.16, Ryvu Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ryvu Therapeutics's current Debt-to-Equity of 1.78 is 1012.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ryvu Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryvu Therapeutics's current Debt-to-Equity is 1.78, which is 5833% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current Debt-to-Equity of 1.78. The stock's GF Value™ is zł77.23, compared to a current price of zł30.25 — trading 60.8% below its estimated fair value. The current Debt-to-Equity is 1.78, which is 5833% above median its 10-year median of 0.03 and 1012.5% above the Biotechnology industry median of 0.16. Ryvu Therapeutics' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current Debt-to-Equity is 1.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of zł30.25 is trading 60.8% below its estimated GF Value™ of zł77.23.
Key valuation signals for LTS:0RKT:
Debt-to-Equity: 1.78 (5833% above median its 10-year median of 0.03)
GF Value™: zł77.23 vs. price of zł30.25 (60.8% below fair value)
Industry Position: 1012.5% above the Biotechnology median (#891 of 954)
No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
65GF Score
Get the complete analysis for LTS:0RKT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKT has been successfully added to your 
